Eli Lilly, Dell Among Stocks To Watch As Market Leadership Shifts

As AI-related stocks weaken, investors are rotating into other sectors, such as energy and health care.

Investors Business Daily • 9 hours ago

This Catalyst Makes Eli Lilly a Top Growth Stock in 2026

Eli Lilly (NYSE:LLY | LLY Price Prediction) has accelerated despite its $1 trillion scale.

24/7 Wall Street • Jul 24, 2026

Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads

Novo Nordisk said on Friday it is seeking a preliminary U.S. ​court injunction to immediately block obesity ‌and diabetes drug advertisements by Eli Lilly , in a further escalation of the rivalry ​between the two groups.

Reuters • Jul 24, 2026

Eli Lilly Stock In A Buy Zone, Set To Ride The Peptide Wave

Eli Lilly stock hit an all-time high of 1,249.50 before pulling back into a buy zone above a pivot of 1,133.95.

Investors Business Daily • Jul 24, 2026

LLY's Retatrutide Nears 2027 Filing With Two More Phase III Wins

Eli Lilly's retatrutide meets the primary endpoint in the phase III TRIUMPH-2 & TRIUMPH-3 studies, supporting planned regulatory submissions for obesity in 2027.

Zacks Investment Research • Jul 24, 2026

Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors?

Eli Lilly's ads don't account for a new, higher dose of Novo Nordisk's Wegovy. Lilly has been winning the race to dominate the GLP-1 drug market.

The Motley Fool • Jul 24, 2026

2 Top Growth Stocks to Buy Right Now Without Any Hesitation

Eli Lilly has just begun tapping into the massive opportunity in chronic weight management. Intuitive Surgical can bounce back thanks to innovation, a strong moat, and a large addressable market.

The Motley Fool • Jul 24, 2026

Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads

Friday's preliminary injunction request escalates legal proceedings initiated earlier this week.

WSJ • Jul 24, 2026

As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize

The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.

Barrons • Jul 24, 2026

Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials

Eli Lilly said it will file for approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, as it succeeds in two more late-stage trials.  The drug delivered significant weight loss and improvements in a key measure of blood sugar levels in adults with obesity and either Type 2 diabetes or established cardiovascular disease.

CNBC • Jul 23, 2026